TSS
BCLI

Two Sigma Securities’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Two Sigma Securities’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,153
Closed -$20.4K – 1512
2025
Q1 		$20.4K Buy
16,153
+4,853
+43% +$8.59K ﹤0.01% 1098
2024
Q4 		$25.7K Buy
11,300
+9,980
+756% +$18.4K ﹤0.01% 1274
2024
Q3 		$4.56K Sell
1,320
-5,481
-81% -$25.9K ﹤0.01% 2673
2024
Q2 		$34.5K Buy
+6,801
New +$51K ﹤0.01% 2623
2023
Q4 		– Sell
-2,685
Closed -$8.06K – 3022
2023
Q3 		$8.06K Buy
+2,685
New +$61K ﹤0.01% 2733

Other funds holding BCLI

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCM
Gunderson Capital Management Mt. Pleasant, South Carolina $239M AUM 122.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $1.7B AUM 39.15% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
AIP
Almanack Investment Partners Wayne, Pennsylvania $592M AUM 25.27% 1-Year Est. Return

Two Sigma Securities's BCLI Position: Q2 2025 in Review

Two Sigma Securities sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2025, closing a stake of 16,153 shares — an estimated $20.4K sold.

Two Sigma Securities first reported a position in BCLI in Q3 2023 and held it in 5 quarters. The position peaked at $34.5K in Q2 2024. 34 funds tracked by Wall St. Rank hold BCLI as of Q2 2025.

  • Two Sigma Securities reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2025 after selling out during the quarter.
  • Two Sigma Securities sold 16,153 BRAINSTORM CELL THERAPUTC shares in Q2 2025, an estimated $20.4K.
  • Two Sigma Securities first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2023 and held it in 5 quarters.
  • Two Sigma Securities's BRAINSTORM CELL THERAPUTC position peaked at $34.5K in Q2 2024.
  • 34 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2025.

Based on Two Sigma Securities's 13F filing for Q2 2025, filed 14 Aug 2025.